Pregled bibliografske jedinice broj: 1194366
Kronična urtikarija: novosti u patogenezi i liječenju
Kronična urtikarija: novosti u patogenezi i liječenju // 7. kongres hrvatskih dermatovenerologa s međunarodnim sudjelovanjem
Vodice, Hrvatska, 2022. 63T2SAAFPPG8N6SPZ, 1 (pozvano predavanje, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 1194366 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Kronična urtikarija: novosti u patogenezi i liječenju
(Chronic urticaria: update on the pathogensis and emerging
treatments)
Autori
Peternel, Sandra
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
7. kongres hrvatskih dermatovenerologa s međunarodnim sudjelovanjem
/ - , 2022
Skup
7. kongres hrvatskih dermatovenerologa s međunarodnim sudjelovanjem
Mjesto i datum
Vodice, Hrvatska, 05.05.2022. - 08.05.2022
Vrsta sudjelovanja
Pozvano predavanje
Vrsta recenzije
Domaća recenzija
Ključne riječi
chronic urticaria ; angioedema ; omalizumab ; autoimmunity ; Bruton tyrosine kinase
Sažetak
Chronic spontaneous urticaria (CSU) is characterized by typically short-lived wheals, angioedema or both, which occur spontaneously and last longer than 6 weeks. This term is used for the most common form of chronic urticaria (CU). The annual prevalence of CU is 0.5% to 2.3%, and its lifetime prevalence is 1.8% across several countries in the United States and Europe. Omalizumab is the only currently approved treatment for antihistamine-refractory CSU, and additional and better treatments for CSU and other subtypes of CU are needed. Objective of the presentation is to provide an update on the pathogenesis of CSU and to discuss novel therapeutic agents that are under development for the treatment of CU/CSU. This update will cover recent findings on the pathogenesis of CSU regarding its two endotypes: type I autoimmune (or autoallergic) CSU, triggered by IgE to autoallergens, and type IIb autoimmune CSU, which is due to mast cell-directed autoantibodies. Several reports suggest that type I autoimmune and type IIb autoimmune CSU patients differ in their disease features, laboratory markers, and response to omalizumab treatment. Newer therapeutical agents are emerging that may offer additional alternatives to antihistamines and omalizumab for CU/CSU patients, including anti-IgE agents, anti-cytokine and anti-receptor biologics, and BTK inhibitors, which will be reviewed.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka,
Sveučilište u Rijeci
Profili:
Sandra Peternel
(autor)